Best of ASCO - 2014 Annual Meeting

 

Welcome

Local-Regional

Genitourinary (Prostate) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist).

Susan F. Slovin

TPS5101

A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).

Simon Pacey

5081

Adjuvant versus salvage radiation therapy in men with high risk features after radical prostatectomy: Survey of North American genitourinary expert radiation oncologists.

Shearwood McClelland

e17078

Apalutamide + abiraterone + leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa).

Sean Matthew McBride

TPS5100

Combination of a therapeutic cancer vaccine and immune checkpoint inhibitors in prostate cancer.

Ravi Amrit Madan

5084

Does PSA 10-20 impact pathologic progression and secondary treatments in men with Gleason 6 on biopsy? Implications for active surveillance in intermediate risk patients.

Fernando Caumont

e17081

Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy.

James L. Gulley

5083

Impact of prostate cancer diagnosis and type of treatment on the health-related quality of life and urological dysfunction at 3 years: A case-control study.

Florence Menegaux

e17084

Long-term androgen deprivation, with or without radiotherapy, in locally-advanced prostate cancer: Updated results from a phase III randomized trial.

Paul Sargos

5080

Neoadjuvant androgen deprivation therapy and enzalutamide: Imaging and pathological responses.

David James VanderWeele

5082

Perioperative and 90-day complication rates in patients with localized prostate cancer treated with high intensity focused ultrasound (HIFU): A prospective case series study.

Claudio Bovolenta Murta

e17083

Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.

Eugene Shenderov

TPS5099

Self-management in prostate cancer survivors: A randomized controlled trial.

Ted A. Skolarus

5011

Stereotactic body radiotherapy for low and intermediate risk prostate cancer: Four-year outcomes.

Mahadev Potharaju

e17082

Survival outcomes for young men with localized intermediate-risk prostate cancer: An analysis of the NCDB.

Graham Boyd

e17085

Ten year treatment outcomes of radical prostatectomy vs external beam radiation therapy vs brachytherapy for 1,503 patients with intermediate risk prostate cancer.

Barry W. Goy

5079